A Phase 3 interventional study of Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg and Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg in Asthma, sponsored by Bond Avillion 2 Development LP. Completed at 345 sites in 11 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2022-09-28.
Sponsored by Bond Avillion 2 Development LP · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.
Among the 1,695 studies in Asthma with a site in United States, this one is the 17th largest by enrollment of the 1,353 interventional ones that give a count, is one of 68 that started in 2018, is one of 254 in phase 3, and was the 1,280th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, China and 2 more countries
Ages 18–85
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
Spiro Medical, Inc. · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 12–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,695 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 151 · Phase 2 337 · Phase 3 276 · Phase 4 158
First in 1990; this study’s year is marked. 68 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,132 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 1,353 interventional studies, 112 across the 330 observational. Of the 1,402 that completed or were terminated, 626 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
642 of 1,695 have an industry lead sponsor. The 10 most frequent:
Bond Avillion 2 Development LP is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Bond Avillion 2 Development LP has 4 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
85 of the studies in Asthma with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,695 studies in Asthma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Receiving 1 of the following scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Budesonide/albuterol sulfate, BDA MDI, PT027 high dose
Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg
Budesonide/albuterol sulfate, BDA MDI, PT027 low dose
Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg
Albuterol sulfate MDI, PT007
Drug: Albuterol sulfate metered-dose inhaler 180 μg
Budesonide/albuterol sulfate combination inhalation aerosol
Budesonide/albuterol sulfate combination inhalation aerosol
Albuterol sulfate inhalation aerosol
Number of Participants With a Severe Asthma Exacerbation Event
Time to first severe asthma exacerbation will be calculated as the time from randomization until the start date of the first severe asthma exacerbation. An asthma exacerbation will be considered severe if it results in at least one of the following: a temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening (a single depo-injectable dose of corticosteroids will be considered equivalent), an emergency room or urgent care visit (\<24 hours in the facility for evaluation and treatment) due to asthma that required systemic corticosteroids, or an in-patient hospitalization (admission to an in-patient facility and/or ≥ 24 hours in a healthcare facility) due to asthma. The descriptive summary shows the number of participants with a severe exacerbation event, occurring between the date of randomization up to the date of randomized treatment discontinuation or a change in maintenance therapy.
Time frame: From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
Annualized Severe Exacerbation Rate
The annualized severe exacerbation rate (severe exacerbations per year) is estimated from a negative binomial model with treatment, age group, region, and number of severe exacerbations in the last 12 months prior to randomization as categorical covariates. The logarithm of the time at risk is included as an offset variable.
Time frame: From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
Total Annualized Dose of Systemic Corticosteroid (SCS)
This endpoint includes all systemic corticosteroids (SCS) taken in response to a severe exacerbation event from randomization up to randomized treatment discontinuation or a change in maintenance therapy. All SCS are standardized to equipotent doses of prednisone before deriving the total dose. The total annualized dose is calculated as the total dose of SCS divided by the duration of the randomized treatment period.
Time frame: From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24
The ACQ-5 consists of 5 questions on symptom control, with each scored on a 7-point scale (0 = excellent asthma control; 6 = extremely poor control). The overall score (0 = excellent asthma control; 6 = extremely poor control, so a lower score is the better outcome) is the mean of the 5 symptom items. A responder is defined as a participant with a decrease from baseline to Week 24 overall ACQ-5 score of 0.5 or more. ACQ-5 is not validated for children less than 6 years old, data for participants who were 4 or 5 years old was excluded from the analysis of ACQ-5.
Time frame: From baseline to Week 24
Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24
The AQLQ+12 consists of 32 questions in 4 domains and is assessed on separate 7-point Likert scales from 1 to 7, with higher values indicating better health-related quality of life. The overall score is the mean of all responses. A responder is defined as a participant with an increase from baseline to week 24 AQLQ-12 score of at least 0.5.
Time frame: From baseline to 24 weeks
The first subject enrolled on 13 December 2018 and the last subject completed the study on 07 February 2022. Subjects were enrolled at 347 study centers worldwide (Argentina, Canada, Czechia, Germany, Serbia, Slovakia, South Africa, Spain, Ukraine, United Kingdom and the United States).
| Milestone | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg |
|---|---|---|---|
| Started | 1016 | 1057 | 1059 |
| Completed | 915 | 933 | 916 |
| Not completed | 101 | 124 | 143 |
| Withdrew: Randomized and did not receive randomized study treatment | 1 | 2 | 2 |
| Withdrew: Withdrawal by subject | 52 | 62 | 74 |
| Withdrew: Death | 4 | 2 | 2 |
| Withdrew: Adverse event | 7 | 7 | 8 |
| Withdrew: A single severe exacerbation event lasting >20 days | 0 | 1 | 2 |
| Withdrew: >= 3 severe exacerbation events within a 3 month period | 1 | 4 | 4 |
| Withdrew: >= 5 total severe exacerbation events | 0 | 1 | 1 |
| Withdrew: Protocol violation | 5 | 6 | 8 |
| Withdrew: Pregnancy | 1 | 0 | 3 |
| Withdrew: Lost to follow-up | 19 | 25 | 21 |
| Withdrew: Condition under investigation worsened | 2 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 2 | 2 |
| Withdrew: Other reasons | 8 | 12 | 15 |
Time to first severe asthma exacerbation will be calculated as the time from randomization until the start date of the first severe asthma exacerbation. An asthma exacerbation will be considered severe if it results in at least one of the following: a temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening (a single depo-injectable dose of corticosteroids will be considered equivalent), an emergency room or urgent care visit (\<24 hours in the facility for evaluation and treatment) due to asthma that required systemic corticosteroids, or an in-patient hospitalization (admission to an in-patient facility and/or ≥ 24 hours in a healthcare facility) due to asthma. The descriptive summary shows the number of participants with a severe exacerbation event, occurring between the date of randomization up to the date of randomized treatment discontinuation or a change in maintenance therapy.
| Participants | BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | AS MDI 180 μg (Full Analysis Set; >=12 Years) | BDA MDI 80/180 μg (Full Analysis Set) | AS MDI 180 μg (Full Analysis Set) |
|---|---|---|---|---|
| Number of Participants With a Severe Asthma Exacerbation Event | 207 | 266 | 241 | 276 |
The annualized severe exacerbation rate (severe exacerbations per year) is estimated from a negative binomial model with treatment, age group, region, and number of severe exacerbations in the last 12 months prior to randomization as categorical covariates. The logarithm of the time at risk is included as an offset variable.
| Severe exacerbations per year | BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | AS MDI 180 μg (Full Analysis Set; >=12 Years) | BDA MDI 80/180 μg (Full Analysis Set) | AS MDI 180 μg (Full Analysis Set) |
|---|---|---|---|---|
| Annualized Severe Exacerbation Rate | 0.45 (0.34 to 0.60) | 0.59 (0.44 to 0.78) | 0.49 (0.37 to 0.64) | 0.61 (0.46 to 0.80) |
This endpoint includes all systemic corticosteroids (SCS) taken in response to a severe exacerbation event from randomization up to randomized treatment discontinuation or a change in maintenance therapy. All SCS are standardized to equipotent doses of prednisone before deriving the total dose. The total annualized dose is calculated as the total dose of SCS divided by the duration of the randomized treatment period.
| Milligram(s) | BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | AS MDI 180 μg (Full Analysis Set; >=12 Years) | BDA MDI 80/180 μg (Full Analysis Set) | AS MDI 180 μg (Full Analysis Set) |
|---|---|---|---|---|
| Total Annualized Dose of Systemic Corticosteroid (SCS) | 86.2 (0 to 3678) | 129.3 (0 to 18941) | 95.5 (0 to 4974) | 127.1 (0 to 18941) |
The ACQ-5 consists of 5 questions on symptom control, with each scored on a 7-point scale (0 = excellent asthma control; 6 = extremely poor control). The overall score (0 = excellent asthma control; 6 = extremely poor control, so a lower score is the better outcome) is the mean of the 5 symptom items. A responder is defined as a participant with a decrease from baseline to Week 24 overall ACQ-5 score of 0.5 or more. ACQ-5 is not validated for children less than 6 years old, data for participants who were 4 or 5 years old was excluded from the analysis of ACQ-5.
| Participants | BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | AS MDI 180 μg (Full Analysis Set; >=12 Years) | BDA MDI 80/180 μg (Full Analysis Set) | AS MDI 180 μg (Full Analysis Set) |
|---|---|---|---|---|
| Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24 | 677 | 630 | 681 | 650 |
The AQLQ+12 consists of 32 questions in 4 domains and is assessed on separate 7-point Likert scales from 1 to 7, with higher values indicating better health-related quality of life. The overall score is the mean of all responses. A responder is defined as a participant with an increase from baseline to week 24 AQLQ-12 score of at least 0.5.
| Participants | BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) | BDA MDI 80/180 μg (Full Analysis Set; >=12 Years) | AS MDI 180 μg (Full Analysis Set; >=12 Years) |
|---|---|---|---|
| Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24 | 508 | 489 | 461 |
Collected over Adverse events (AEs) were collected from the time of signed informed consent/assent and up to the safety follow up period. Reported AEs are those that occurred from the date of first dose of randomized treatment up to the date of treatment discontinuation, which per protocol, was expected to be at least 24 weeks. The mean and median duration of exposure to randomized treatment for the reporting period for all participants was 44 and 48 weeks, respectively.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BDA MDI (PT027) 160/180 μg | 4/1,015 (0.4%) | 53/1,015 (5.2%) | 244/1,015 (24%) |
| BDA MDI (PT027) 80/180 μg | 2/1,055 (0.2%) | 40/1,055 (3.8%) | 253/1,055 (24%) |
| AS MDI (PT007) 180 µg | 2/1,057 (0.2%) | 48/1,057 (4.5%) | 243/1,057 (23%) |
| Event | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 7/1015 | 8/1055 | 20/1057 |
| COVID-19Infections and infestations | 11/1015 | 5/1055 | 8/1057 |
| PneumoniaInfections and infestations | 5/1015 | 4/1055 | 2/1057 |
| COVID-19 pneumoniaInfections and infestations | 3/1015 | 4/1055 | 5/1057 |
| Cholecystitis acuteHepatobiliary disorders | 3/1015 | 0/1055 | 0/1057 |
| InfluenzaInfections and infestations | 0/1015 | 3/1055 | 0/1057 |
| Urinary tract infectionInfections and infestations | 0/1015 | 0/1055 | 3/1057 |
| Atrial fibrillationCardiac disorders | 0/1015 | 2/1055 | 0/1057 |
| Accelerated hypertensionVascular disorders | 1/1015 | 0/1055 | 0/1057 |
| Deep vein thrombosisVascular disorders | 1/1015 | 0/1055 | 0/1057 |
| Event | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 76/1015 | 61/1055 | 54/1057 |
| HeadacheNervous system disorders | 44/1015 | 50/1055 | 49/1057 |
| COVID-19Infections and infestations | 33/1015 | 47/1055 | 38/1057 |
| Upper respiratory tract infectionInfections and infestations | 26/1015 | 31/1055 | 26/1057 |
| Back painMusculoskeletal and connective tissue disorders | 27/1015 | 23/1055 | 20/1057 |
| BronchitisInfections and infestations | 25/1015 | 27/1055 | 28/1057 |
| HypertensionVascular disorders | 22/1015 | 27/1055 | 26/1057 |
| SinusitisInfections and infestations | 15/1015 | 17/1055 | 25/1057 |
| InfluenzaInfections and infestations | 21/1015 | 20/1055 | 14/1057 |
Of the 3,132 participants randomized, the full analysis set across all ages comprises 3,127 participants as one participant was randomized and did not receive randomized study treatment, and four participants were randomized in error and did not receive randomized study treatment. These five participants have therefore been excluded from the summaries of baseline characteristics, efficacy and safety.
| Age, Continuous(years) | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg | Total |
|---|---|---|---|---|
| Mean | 50.6 ± 15.05 | 48.5 ± 16.71 | 49.1 ± 17.22 | 49.4 ± 16.39 |
| Age, Customized(Participants) | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg | Total |
|---|---|---|---|---|
| Children (>=4 to <12 years) | 0 | 41 | 42 | 83 |
| Adolescents (>=12 to <18 years) | 34 | 32 | 34 | 100 |
| Adults (>=18 to <65 years) | 789 | 805 | 784 | 2378 |
| Elderly (>=65 years) | 192 | 177 | 197 | 566 |
| Sex: Female, Male(Participants) | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg | Total |
|---|---|---|---|---|
| Female | 647 | 686 | 695 | 2028 |
| Male | 368 | 369 | 362 | 1099 |
| Ethnicity (NIH/OMB)(Participants) | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 235 | 261 | 316 | 812 |
| Not Hispanic or Latino | 780 | 794 | 741 | 2315 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 29 | 33 | 23 | 85 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 139 | 141 | 137 | 417 |
| White | 820 | 848 | 869 | 2537 |
| More than one race | 18 | 20 | 24 | 62 |
| Unknown or Not Reported | 8 | 12 | 4 | 24 |
| Region of Enrollment(Participants) | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg | Total |
|---|---|---|---|---|
| Canada | 19 | 11 | 12 | 42 |
| Argentina | 157 | 200 | 207 | 564 |
| United States | 274 | 275 | 290 | 839 |
| Czechia | 74 | 64 | 73 | 211 |
| Ukraine | 156 | 150 | 128 | 434 |
| South Africa | 106 | 120 | 115 | 341 |
| United Kingdom | 9 | 15 | 10 | 34 |
| Slovakia | 25 | 30 | 28 | 83 |
| Serbia | 65 | 54 | 57 | 176 |
| Germany | 109 | 108 | 112 | 329 |
| Spain | 21 | 28 | 25 | 74 |
| Height(Centimeters) | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg | Total |
|---|---|---|---|---|
| Mean | 166.8 ± 9.92 | 165.1 ± 11.45 | 164.4 ± 11.67 | 165.4 ± 11.10 |
| Weight(Kilograms) | BDA MDI (PT027) 160/180 μg | BDA MDI (PT027) 80/180 μg | AS MDI (PT007) 180 µg | Total |
|---|---|---|---|---|
| Mean | 80.5 ± 16.88 | 78.2 ± 18.93 | 78.8 ± 18.47 | 79.2 ± 18.15 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 345 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in Aug 2021, 32 months.
Results were first posted in Sep 2022, 1 year 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 32 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bond Avillion 2 Development LP